Soleno Therapeutics (SLNO) Change in Account Payables (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Change in Account Payables data on file, last reported at -$3.0 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 10.97% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 257.3% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, down 36.32% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$3.0 million, down from $4.3 million in the prior quarter.
• Over the last five years, Change in Account Payables for SLNO reached as high as $4.9 million in Q1 2024 and fell as low as -$4.3 million in Q2 2024.
• Historically, Change in Account Payables has averaged $365235.3 across 5 years, with a median of $198000.0 in 2022.
• On a YoY basis, Change in Account Payables climbed as much as 7482.35% in 2024 and fell as far as 733.92% in 2024.
• Year by year, Change in Account Payables stood at -$547000.0 in 2022, then surged by 106.22% to $34000.0 in 2023, then surged by 7482.35% to $2.6 million in 2024, then jumped by 66.25% to $4.3 million in 2025, then plunged by 169.3% to -$3.0 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$3.0 million in Q1 2026, $4.3 million in Q4 2025, and $1.9 million in Q3 2025.